Vincerx Pharma is a clinical-stage biopharmaceutical company focused on utilizing its development and oncology capabilities to develop therapies intended to address unmet medical needs for the treatment of cancer. Co.'s pipeline consists of enitociclib and a proprietary modular bioconjugation platform, which includes a small molecule drug-conjugate, VIP236 and preclinical antibody drug-conjugates, VIP943 and VIP924. Co. had been granted an exclusive, royalty-bearing, worldwide license under certain Bayer AG patents and know-how to develop, use, manufacture, commercialize, sublicense, and distribute multiple clinical and preclinical stage compounds. We show 12 historical shares outstanding datapoints in our VINC shares outstanding history coverage, used to compute VINC market cap on those dates.
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing VINC market cap history over the course of time is important for investors
interested in comparing VINC's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of VINC versus a peer is one thing; comparing
VINC market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like VINC can fluctuate over the course of history.
With this page we aim to empower investors researching VINC by allowing them to research the VINC market cap history. |
Free VINC Email Alerts:
Video: The Importance of Market Cap
